Rapport Therapeutics initiates coverage with buy rating and $71 target price
RAPP•UBS initiated coverage of Rapport Therapeutics with a buy rating and a $71 target price.
Related News
Westamerica Bancorp Q3 EPS $1.22
WABC•
ExxonMobil projects global electricity demand to rise roughly 65% by 2050
XOM•
Nasdaq trade halt continues; reason not available at 10:41 a.m.
UCFIW•
US research roundup: BlackRock, Microsoft, TransDigm Group
BLK•
Comstock participates in LD Micro 20th Annual Main Event
CHCI•